[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-374356-105":59,"doc-detail-374356-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","adoptive-immune-cell-therapy-for-colorectal-cancer","Adoptive immune cell therapy for colorectal cancer","","Adoptive immune cell therapy for colorectal cancer reviews progress in engineered immune cell approaches for advanced CRC, where conventional treatments offer limited survival benefits. It outlines DC vaccines and CAR/TCR-T and CAR-NK strategies designed to recognize defined tumor antigens, and analyzes why CAR-T faces obstacles from the solid tumor microenvironment. The review further highlights alternative cell types such as CAR-M and CAR-gdT, including lentiviral transduction advances, mechanism and tumor targeting, preclinical evidence, and early-phase clinical trials. Key challenges addressed include improving tumor antigen specificity and overcoming immunosuppressive microenvironments, with combination potential from checkpoint and cytokine therapies to enhance efficacy for clinical translation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adoptive-immune-cell-therapy-for-colorectal-cancer/374356/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adoptive-immune-cell-therapy-for-colorectal-cancer/374356.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is adoptive immune cell therapy considered promising for advanced colorectal cancer?","Question",{"text":113,"@type":114},"Advanced colorectal cancer has limited options and low 5-year survival rates. Immunotherapy, especially immune cell-based approaches, aims to target tumors with enhanced anti-tumor immunity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What challenges limit CAR-T cell therapy in colorectal cancer?",{"text":118,"@type":114},"CAR-T faces difficulties in solid tumor settings because the tumor microenvironment restricts cell infiltration and persistence, weakening therapeutic effects.",{"name":120,"@type":111,"acceptedAnswer":121},"How do CAR-NK cells, CAR-M, and CAR-gdT cells offer alternative strategies?",{"text":122,"@type":114},"These therapies have distinct properties, including the ability to target tumor cells without prior sensitization and a lower risk of severe cytokine release syndrome, and lentiviral transduction supports effective CAR expression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},374356,1790291378,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","TYPE Review  \nPUBLISHED 01 April 2025  \nDOI 10.3389/fimmu.2025.1557906  \nOPEN ACCESS  \nEDITED BY  \nJun Wang,  \nDalhousie University, Canada  \nREVIEWED BY  \nAnna Maria Corsale, University of Palermo, Italy Jim Xiang,  \nSaskatchewan Cancer Agency, Canada  \n*CORRESPONDENCE  \nTongcun Zhang  \n [zhangtongcun@wust.edu.cn](zhangtongcun@wust.edu.cn)[ ](zhangtongcun@wust.edu.cn)Yanyang Tu  \n[tufmmu@188.com](tufmmu@188.com)  \n†These authors have contributed equally to this work and share first authorship  \n‡These authors have contributed equally to this work  \nRECEIVED 09 January 2025  \nACCEPTED 28 February 2025  \nPUBLISHED 01 April 2025  \nCITATION  \nLiu C, Liu N, Zhang T and Tu Y (2025)  \nAdoptive immune cell therapy for colorectal cancer.  \nFront. Immunol. 16:1557906 .  \ndoi: 10.3389/fimmu.2025.1557906  \nCOPYRIGHT  \n© 2025 Liu, Liu, Zhang and Tu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdoptive immune cell therapy for colorectal cancer  \nChenxiao Liu 1†, Nan Liu 1,2†, Tongcun Zhang 1,2*‡ and Yanyang Tu 3,4*‡  \n1Guangdong Province Science and Technology Expert Workstation, Huizhou Central People’s Hospital, Huizhou, Guangdong, China, 2 Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, China, 3Science Research Center, Huizhou Central People’s Hospital, Huizhou, Guangdong, China, 4 Huizhou Central People’s Hospital Academy of Medical Sciences, Huizhou Central People’s Hospital, Huizhou, Guangdong, China  \nColorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide, with limited options for patients at advanced stages. Immunotherapy, particularly immune cell-based therapies, has gained significant attention as an innovative approach for targeting CRC. This review summarizes the progress in various immune cell therapies, including DC vaccine, CAR/TCR-T cells, CAR-NK cells et al, each engineered to recognize and attack cancer cells expressing specific antigens. CAR-T cell therapy, which has been successful in hematologic cancers, faces challenges in CRC due to the solid tumor microenvironment, which limits cell infiltration and persistence. CAR-NK cells, CAR-M and CAR-gdT cells, however, offer alternative strategies due to their unique properties, such as the ability to target tumor cells without prior sensitization and a lower risk of inducing severe cytokine release syndrome. Recent advances in lentiviral transduction have enabled effective expression of CARs on NK and gdT cells, providing promising preclinical results in CRC models. This review explores the mechanisms, tumor targets, preclinical studies, and early-phase clinical trials of these therapies, addressing key challenges such as enhancing spec ificity to tumor antigen s and overcoming the immunosuppressive tumor microenvironment. The potential of combination therapies, including immune checkpoint inhibitors and cytokine therapy, is also discussed some as a means to improve the effectiveness of immune cell-based treatments for CRC. Continued research is essential to translate these promising approaches into clinical settings, offering new hope for CRC patients.  \nKEYWORDS  \nadoptive immune cell therapy (ACT), immune cells, colorectal cancer (CRC), tumor antigens, clinical trials  \n1 Introduction  \nAccording to the latest global cancer burden data for 2020 released by the World Health Organization, there were 19.29 million new cancer cases worldwide in 2020, including 1.93 million cases of colorectal cancer, ranking third. There were 9.96 million cancer deaths worldwide, and co","cbCaigNkigNPl4nO","https://ap.wps.com/l/cbCaigNkigNPl4nO","pdf",1002293,15,"English","# Introduction\n# Adoptive cell therapy overview\n## Historical development and antigen-targeted immunotherapies\n# Immune cell therapies for CRC\n## DC vaccine and other immunotherapies\n## CAR/TCR-T, CAR-NK, CAR-M, and CAR-gdT strategies\n# Mechanisms and tumor targets\n# Preclinical studies and early-phase clinical trials\n# Key challenges and combination strategies","[{\"question\":\"Why is adoptive immune cell therapy considered promising for advanced colorectal cancer?\",\"answer\":\"Advanced colorectal cancer has limited options and low 5-year survival rates. Immunotherapy, especially immune cell-based approaches, aims to target tumors with enhanced anti-tumor immunity.\"},{\"question\":\"What challenges limit CAR-T cell therapy in colorectal cancer?\",\"answer\":\"CAR-T faces difficulties in solid tumor settings because the tumor microenvironment restricts cell infiltration and persistence, weakening therapeutic effects.\"},{\"question\":\"How do CAR-NK cells, CAR-M, and CAR-gdT cells offer alternative strategies?\",\"answer\":\"These therapies have distinct properties, including the ability to target tumor cells without prior sensitization and a lower risk of severe cytokine release syndrome, and lentiviral transduction supports effective CAR expression.\"}]","Adoptive immune cell therapy for colorectal cancer | PDF",1790201508,38]